Genescience Pharmaceuticals Co., Ltd.
rhGH (rDNA origin) injection / Jintropin®AQ Somatropin (liquid form)
• First rhGH liquid pen-type formulation launched on the market in China in 2005
• High quality standard exceeding that of Chinese Pharmacopoeia 2005 and European Pharmacopoeia 2005
Advantages of Jintropin® AQ
• Advanced production techniques
* Patented proprietary secretion technology
Secretion of rhGH from E.coli cytoplasm to periplasm simplifies purification and improves rhGH's biological activity.
* lyophilization process avoided in production
Avoiding lyophilization process decreases the aggregation of rhGH molecules and results in higher biological potency than that of the freeze-dried rhGH
* Special protection reagents and buffer system
• Bioequivalence between Jintropin® AQ and freeze-dried Jintropin®
* Jintropin® AQ shows bioequivalence to Jintropin®
• First ready-to-use liquid rhGH injection in China with a pen injection system
* More convenient by avoiding the need for reconstitution before administration
* More accurate administration with the Jintropin® injection pen
• Improved long-term clinical effect comparing with that of free-dried rhGH
• Excellent patient compliance
Clinical Indications:
• Child growth
• Burns
• Adult growth hormone deficiency
Contact Details
|
Genescience Pharmaceuticals Co., Ltd. No.72 Tianhe Rd, High & New Technology Development Zone Tel: 86-431-85195060 Fax: 86-431-85186819 Email: export@gensci-china.com
Homepage Address http://www.gensci-china.com |
Key Contact: Mr. Frank Liu |
